Tau aggregation in the hippocampal formation: an ageing or a pathological process?

Tauopathy is a concept to describe different genetic or metabolic dysfunctions of tau proteins that generate most of the known dementing disorders. Tauopathy is a degenerating process that also affects the entorhinal formation, and then the hippocampal formation in ageing. In Alzheimer's disease (AD), a disease due to APP dysfunction, a similar tauopathy process in observed in neocortical areas, well correlated to cognitive impairment. One important gap of knowledge is the relationship between tauopathy in the hippocampal formation, ageing, AD, and cognitive impairment. Here we show that the multidisciplinary analysis of numerous brains from non-demented and demented patients suggests the following observations: tauopathy of the hippocampal formation in humans is age-related but not an age-dependent process, also independent of AD, but amplified by APP dysfunctions. Tauopathy in the entorhinal and hippocampal formation could be another type of pathological dysfunction of tau proteins, and a therapeutic target to delay AD. Relevant animal models are desperately needed to address this issue.

[1]  M. Goedert,et al.  Neurofibrillary pathology of Alzheimer's disease and other tauopathies. , 1998, Progress in brain research.

[2]  A. Delacourte,et al.  Dysregulation of human brain microtubule-associated tau mRNA maturation in myotonic dystrophy type 1. , 2001, Human molecular genetics.

[3]  H. Braak,et al.  Neuropathology of Alzheimer’s disease: what is new since A. Alzheimer? , 1999, European Archives of Psychiatry and Clinical Neuroscience.

[4]  M. Mesulam.  Neuroplasticity Failure in Alzheimer's Disease Bridging the Gap between Plaques and Tangles , 1999, Neuron.

[5]  J. Morris,et al.  Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease , 1999, Annals of neurology.

[6]  D. Selkoe,et al.  The origins of Alzheimer disease: a is for amyloid. , 2000, JAMA.

[7]  W. Markesbery,et al.  Alzheimer's neurofibrillary pathology and the spectrum of cognitive function: Findings from the Nun Study , 2002, Annals of neurology.

[8]  C. Duyckaerts,et al.  Prevalence, Incidence and Duration of Braak’s Stages in the General Population: Can We Know? , 1997, Neurobiology of Aging.

[9]  A. Delacourte,et al.  Progressive decrease of amyloid precursor protein carboxy terminal fragments (APP‐CTFs), associated with tau pathology stages, in Alzheimer's disease , 2002, Journal of neurochemistry.

[10]  C. Duyckaerts,et al.  Diagnosis and Staging of Alzheimer Disease , 1997, Neurobiology of Aging.

[11]  M. Kidd.  ALZHEIMER'S DISEASE--AN ELECTRON MICROSCOPICAL STUDY. , 1964, Brain : a journal of neurology.

[12]  A. Delacourte,et al.  The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer’s disease , 1999, Neurology.

[13]  M. Ball,et al.  Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories: Concurrences and Cautions , 1997, Neurobiology of Aging.

[14]  H. Braak,et al.  Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories , 1997, Neurobiology of Aging.

[15]  A. Delacourte,et al.  Tau pathology: a marker of neurodegenerative disorders , 2000, Current opinion in neurology.

[16]  L Carlin,et al.  Neocortical neurofibrillary tangles correlate with dementia severity in Alzheimer's disease. , 1995, Archives of neurology.

[17]  M. Ball,et al.  A topographical pathway by which histopathological lesions disseminate through the brain of patients with Alzheimer's disease , 1991 .

[18]  Patrick R. Hof,et al.  Tau protein isoforms, phosphorylation and role in neurodegenerative disorders 1 1 These authors contributed equally to this work. , 2000, Brain Research Reviews.

[19]  A. Alzheimer.  Uber eine eigenartige Erkrankung der Hirnrinde , 1907 .